Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended				12 Months Ended
	Aug. 31, 2021	Aug. 31, 2018	Oct. 31, 2016	Jun. 30, 2016	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2020	Jan. 31, 2017
Carna Collaboration Agreement [Member]
Loss Contingencies [Line Items]
Upfront payment				$ 0.9
Upfront License Fee						$ 0.3
Asset Purchase Agreement [Member]
Loss Contingencies [Line Items]
Upfront payment paid		$ 3.0
Aggregate milestone payment					$ 190.0
Asset Purchase Agreement [Member] | Approval from FDA [Member]
Loss Contingencies [Line Items]
Milestone payment					25.0
AstraZeneca License Agreement [Member]
Loss Contingencies [Line Items]
Aggregate milestone payment	$ 208.0
Upfront payment	8.0
AstraZeneca License Agreement [Member] | Drug Products and Drug Substance [Member]
Loss Contingencies [Line Items]
Research and development payable	$ 0.9
CPF License Agreements [Member]
Loss Contingencies [Line Items]
Upfront payment			$ 7.0
Additional milestone payment payable					319.5
CPF License Agreements [Member] | Transfer of Phase 1 Clinical Trials [Member]
Loss Contingencies [Line Items]
Milestone payment								$ 2.0
CPF License Agreements [Member] | First patient first trial post amendment [Member]
Loss Contingencies [Line Items]
Milestone payment							$ 2.0
CPF License Agreement Amendment [Member]
Loss Contingencies [Line Items]
Additional milestone payment payable					$ 290.0